SG11202001441WA - Polymorphic form of tg02 - Google Patents
Polymorphic form of tg02Info
- Publication number
- SG11202001441WA SG11202001441WA SG11202001441WA SG11202001441WA SG11202001441WA SG 11202001441W A SG11202001441W A SG 11202001441WA SG 11202001441W A SG11202001441W A SG 11202001441WA SG 11202001441W A SG11202001441W A SG 11202001441WA SG 11202001441W A SG11202001441W A SG 11202001441WA
- Authority
- SG
- Singapore
- Prior art keywords
- polymorphic form
- polymorphic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762547157P | 2017-08-18 | 2017-08-18 | |
| PCT/US2018/000264 WO2019035985A1 (en) | 2017-08-18 | 2018-08-17 | Polymorphic form of tg02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001441WA true SG11202001441WA (en) | 2020-03-30 |
Family
ID=65359869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001441WA SG11202001441WA (en) | 2017-08-18 | 2018-08-17 | Polymorphic form of tg02 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10544162B2 (en) |
| EP (1) | EP3668876B1 (en) |
| JP (1) | JP7250764B2 (en) |
| KR (1) | KR20200078481A (en) |
| AU (1) | AU2018317865B2 (en) |
| CA (1) | CA3073270A1 (en) |
| IL (1) | IL272697B2 (en) |
| MX (1) | MX2020001875A (en) |
| RU (1) | RU2020111019A (en) |
| SG (1) | SG11202001441WA (en) |
| TW (1) | TWI785098B (en) |
| WO (1) | WO2019035985A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021012977A (en) | 2016-03-24 | 2022-10-03 | Cothera Biosciences Inc | Treatment of cancer with tg02. |
| WO2020219606A1 (en) | 2019-04-22 | 2020-10-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of erk5 inhibitors for treating gliomas in pediatric subjects |
| CN110664760B (en) * | 2019-10-28 | 2020-10-23 | 浙江大学 | VEGFR targeted inhibitor loaded drug carrier and preparation method and application thereof |
| WO2024031406A1 (en) * | 2022-08-10 | 2024-02-15 | Xiang Li | Idh mutations as biomarkers for zotiraciclib therapy |
| CN115429793A (en) * | 2022-08-15 | 2022-12-06 | 复旦大学附属中山医院 | Application of compound in preparation of medicine for treating hepatocellular carcinoma |
| CN115305251B (en) * | 2022-08-30 | 2023-06-27 | 中国农业科学院北京畜牧兽医研究所 | Application of AP2-MYBL2 molecular module in regulating and controlling proanthocyanidin biosynthesis |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR8108820A (en) | 1980-09-24 | 1982-08-24 | Cetus Corp | DIAGNOSTIC PROCESS AND PROBE |
| ATE53862T1 (en) | 1982-01-22 | 1990-06-15 | Cetus Corp | METHODS FOR THE CHARACTERIZATION OF HLA AND THE CDNS TEST AGENTS USED THEREIN. |
| US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| KR100942863B1 (en) | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | Human ctla-4 antibodies and their uses |
| DE10161767T1 (en) | 2002-07-03 | 2018-06-07 | Honjo Tasuku | Immunopotentiating compositions containing an anti-PD-L1 antibody |
| CA2598239C (en) * | 2005-02-18 | 2019-10-29 | Abraxis Bioscience, Inc. | Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy |
| AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| BRPI0618552B8 (en) | 2005-11-16 | 2021-05-25 | Cell Therapeutics Inc | pyrimidine derivative compounds linked to oxygen, pharmaceutical composition that includes said compounds, method of synthesis of the compounds and therapeutic uses thereof |
| SI2170959T1 (en) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
| PE20110435A1 (en) | 2008-08-25 | 2011-07-20 | Amplimmune Inc | ANTAGONIST COMPOSITIONS OF PD-1 |
| CN114835812A (en) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | anti-PD-L1 antibodies and their use for enhancing T cell function |
| EP2418955A4 (en) * | 2009-04-15 | 2012-11-21 | Poniard Pharmaceuticals Inc | High bioavailability oral picoplatin anti-cancer therapy |
| JP4965623B2 (en) | 2009-09-30 | 2012-07-04 | インターナショナル・ビジネス・マシーンズ・コーポレーション | Method, system, and program for supporting input of execution parameters of predetermined software to input field |
| WO2011097525A1 (en) * | 2010-02-05 | 2011-08-11 | Tragara Pharmaceuticals, Inc. | Solid state forms of macrocyclic kinase inhibitors |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| US20130071403A1 (en) | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| AU2012344260B2 (en) | 2011-11-28 | 2017-09-07 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| SG11201407190TA (en) | 2012-05-15 | 2014-12-30 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| AR091649A1 (en) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
| WO2014022332A1 (en) | 2012-07-31 | 2014-02-06 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
| ME03796B (en) | 2013-03-15 | 2021-04-20 | Glaxosmithkline Ip Dev Ltd | Anti-lag-3 binding proteins |
| HUE046674T2 (en) | 2013-09-11 | 2020-03-30 | Medimmune Ltd | Anti-b7-h1 antibodies for treating tumors |
| JP6538707B2 (en) | 2014-03-07 | 2019-07-03 | ユニバーシティ ヘルス ネットワーク | Methods and compositions for modulating an immune response |
| KR102442436B1 (en) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Antibody molecules to lag-3 and uses thereof |
| MX2021012977A (en) | 2016-03-24 | 2022-10-03 | Cothera Biosciences Inc | Treatment of cancer with tg02. |
-
2018
- 2018-08-17 AU AU2018317865A patent/AU2018317865B2/en active Active
- 2018-08-17 RU RU2020111019A patent/RU2020111019A/en unknown
- 2018-08-17 MX MX2020001875A patent/MX2020001875A/en unknown
- 2018-08-17 IL IL272697A patent/IL272697B2/en unknown
- 2018-08-17 CA CA3073270A patent/CA3073270A1/en active Pending
- 2018-08-17 SG SG11202001441WA patent/SG11202001441WA/en unknown
- 2018-08-17 JP JP2020508985A patent/JP7250764B2/en active Active
- 2018-08-17 TW TW107128900A patent/TWI785098B/en active
- 2018-08-17 KR KR1020207007701A patent/KR20200078481A/en not_active Application Discontinuation
- 2018-08-17 EP EP18846214.7A patent/EP3668876B1/en active Active
- 2018-08-17 WO PCT/US2018/000264 patent/WO2019035985A1/en unknown
- 2018-08-17 US US15/998,872 patent/US10544162B2/en active Active
-
2020
- 2020-01-24 US US16/751,969 patent/US20200262843A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL272697B1 (en) | 2023-08-01 |
| KR20200078481A (en) | 2020-07-01 |
| CN111372934A (en) | 2020-07-03 |
| WO2019035985A1 (en) | 2019-02-21 |
| IL272697B2 (en) | 2023-12-01 |
| TW201920199A (en) | 2019-06-01 |
| EP3668876B1 (en) | 2024-01-24 |
| US20190055263A1 (en) | 2019-02-21 |
| US20200262843A1 (en) | 2020-08-20 |
| AU2018317865B2 (en) | 2023-03-16 |
| JP7250764B2 (en) | 2023-04-03 |
| CA3073270A1 (en) | 2019-02-21 |
| JP2020531463A (en) | 2020-11-05 |
| AU2018317865A1 (en) | 2020-03-19 |
| IL272697A (en) | 2020-04-30 |
| TWI785098B (en) | 2022-12-01 |
| MX2020001875A (en) | 2020-07-29 |
| RU2020111019A3 (en) | 2022-03-18 |
| EP3668876A1 (en) | 2020-06-24 |
| EP3668876A4 (en) | 2021-04-28 |
| RU2020111019A (en) | 2021-09-20 |
| US10544162B2 (en) | 2020-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272888A (en) | Novel uses of piperidinyl-indole derivatives | |
| IL268915A (en) | Polymorphic compounds and uses thereof | |
| HK1252845A1 (en) | Crystalline form of lorlatinib free base | |
| IL263050B (en) | Derivatives of sobetirome | |
| IL269409A (en) | Combinations of chk1- and wee1 - inhibitors | |
| IL272697A (en) | Polymorphic form of tg02 | |
| IL292245A (en) | Polymorphic forms of rad1901-2hcl | |
| IL274627A (en) | Solid state form of valbenazine | |
| PL3532457T3 (en) | Crystalline forms of hydroxynorketamine | |
| ZA202003487B (en) | Polymorphs | |
| EP3894768C0 (en) | Methods of cryo-curing | |
| GB201407807D0 (en) | Polymorphic form | |
| IL270961A (en) | Crystalline form of n-butyldeoxygalactonojirimycin | |
| GB201407820D0 (en) | Polymorphic form | |
| GB2553390B (en) | Method of manufacture | |
| IL263363A (en) | Polymorph of nintedanib | |
| GB201407813D0 (en) | Polymorphic form | |
| GB201703041D0 (en) | Installation of mono-pile | |
| GB201704816D0 (en) | Method of manufacture | |
| GB201721386D0 (en) | Chrondogy of time-wave | |
| IL270937A (en) | Crystalline forms of seletalisib | |
| GB2567222B (en) | Method of manufacture | |
| PL3629754T3 (en) | Method of preparing adrosera | |
| GB201717104D0 (en) | Polymorphs | |
| GB201707716D0 (en) | Point of interest location specification |